Takeda Pharmaceutical Company
Search results
ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.
Feb 16, 2017 · Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) (“ARIAD”) for $24.00 per share in cash. “We are very pleased to have completed the acquisition of ARIAD Pharmaceuticals.
Jan 9, 2017 · ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers.
Jan 9, 2017 · Takeda, a Japanese pharmaceutical company, bought Ariad, a US-based biotech firm, to expand its oncology portfolio and pipeline. The deal closed in February 2017 and was valued at $24 per share in cash.
Feb 17, 2017 · “We are very pleased to have completed the acquisition of ARIAD Pharmaceuticals. The addition of ARIAD’s innovative targeted therapies and research and development capabilities strengthens and diversifies our oncology business, positioning Takeda for sustainable long-term growth in this priority therapeutic area,” said Christophe Weber ...
Jan 9, 2017 · Takeda Pharmaceutical said that it plans to buy Ariad Pharmaceuticals in a $5.2bn tie-up as the Japanese group looks to bolster its cancer-drug portfolio.
Jan 10, 2017 · Japan's Takeda Pharmaceutical Co Ltd said it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion, to beef up its oncology pipeline.
